Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients With Coronavirus Disease-2019 During Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch

Raymund R. Razonable, John C. O'Horo, Sara N. Hanson, Richard F. Arndt, Leigh L. Speicher, Teresa A. Seville, Scott T. Hall, Marsha L. Pike, Alexander Heyliger, Jennifer J. Larsen, Ravindra Ganesh, Sidna Tulledge-Scheitel

Research output: Contribution to journalArticlepeer-review

Abstract

The effectiveness of bebtelovimab in real-world settings has not been assessed. In this retrospective cohort study of 3607 high-risk patients, bebtelovimab was used more commonly than nirmatrelvir-ritonavir for treatment of coronavirus disease 2019 (COVID-19) among older patients, immunosuppressed patients, and those with multiple comorbid conditions. Despite its use in patients with multiple comorbid conditions, the rate of progression to severe disease after bebtelovimab (1.4% [95% confidence interval, 1.2%-1.7%]) was not significantly different from that for nirmatrelvir-ritonavir treatment (1.2% [.8%-1.5%]). Our findings support the emergency use authorization of bebtelovimab for treatment of COVID-19 during the Omicron epoch dominated by BA.2 and subvariants.

Original languageEnglish (US)
Pages (from-to)1683-1687
Number of pages5
JournalThe Journal of infectious diseases
Volume226
Issue number10
DOIs
StatePublished - Nov 11 2022

Keywords

  • bebtelovimab
  • COVID-19
  • hospitalization
  • monoclonal antibodies
  • nirmatrelvir
  • Paxlovid
  • ritonavir
  • SARS-CoV-2

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients With Coronavirus Disease-2019 During Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch'. Together they form a unique fingerprint.

Cite this